Additionally, compounds that modulate 5-HT2A have been rigorously examined in the context of disorders that affect mood, perception, and memory like MDD [78], but comparatively little has been done to characterize the capacity of 5-HT2A agonists to attenuate TBI-elicited neuropsychiatric disturbances. The gene discussed is HTR2A; the disease is major depressive disorder.